120 related articles for article (PubMed ID: 12187198)
1. Phase II trial of weekly intravenous gemcitabine administration with interferon and interleukin-2 immunotherapy for metastatic renal cell cancer.
Neri B; Doni L; Gemelli MT; Fulignati C; Turrini M; Di Cello V; Dominici A; Maleci M; Mottola A; Ponchietti R; Raugei A; Valsuani G; Cini G
J Urol; 2002 Sep; 168(3):956-8. PubMed ID: 12187198
[TBL] [Abstract][Full Text] [Related]
2. A phase II trial of intravenous gemcitabine and 5-fluorouracil with subcutaneous interleukin-2 and interferon-alpha in patients with metastatic renal cell carcinoma.
Ryan CW; Vogelzang NJ; Stadler WM
Cancer; 2002 May; 94(10):2602-9. PubMed ID: 12173327
[TBL] [Abstract][Full Text] [Related]
3. [Active combination immunochemotherapy with interferon-alpha, interleukin-2 and gemcitabine for four patients with metastatic renal cell carcinoma].
Inoue T; Ohyama C; Hatakeyama S; Horikawa Y; Togashi H; Tsuchiya N; Matsuura S; Satoh S; Sato K; Habuchi T
Hinyokika Kiyo; 2005 Mar; 51(3):165-9. PubMed ID: 15852669
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents.
Tannir NM; Thall PF; Ng CS; Wang X; Wooten L; Siefker-Radtke A; Mathew P; Pagliaro L; Wood C; Jonasch E
J Urol; 2008 Sep; 180(3):867-72; discussion 872. PubMed ID: 18635226
[TBL] [Abstract][Full Text] [Related]
5. Dose-finding/phase II trial: bevacizumab, immunotherapy, and chemotherapy (BIC) in metastatic renal cell cancer (mRCC). Antitumor effects and variations of circulating T regulatory cells (Treg).
Donini M; Buti S; Lazzarelli S; Bozzetti R; Rivoltini L; Camisaschi C; Castelli C; Bearz A; Simonelli C; Lo Re G; Mattioli R; Caminiti C; Passalacqua R;
Target Oncol; 2015 Jun; 10(2):277-86. PubMed ID: 25230695
[TBL] [Abstract][Full Text] [Related]
6. Gemcitabine and interferon-alpha 2b in solid tumors: a phase I study in patients with advanced or metastatic non-small cell lung, ovarian, pancreatic or renal cancer.
Fuxius S; Mross K; Mansouri K; Unger C
Anticancer Drugs; 2002 Oct; 13(9):899-905. PubMed ID: 12394252
[TBL] [Abstract][Full Text] [Related]
7. Phase II trial of weekly intravenous gemcitabine with continuous infusion fluorouracil in patients with metastatic renal cell cancer.
Rini BI; Vogelzang NJ; Dumas MC; Wade JL; Taber DA; Stadler WM
J Clin Oncol; 2000 Jun; 18(12):2419-26. PubMed ID: 10856102
[TBL] [Abstract][Full Text] [Related]
8. Immunochemotherapy with interleukin-2, interferon-alpha and 5-fluorouracil for progressive metastatic renal cell carcinoma: a multicenter phase II study. Dutch Immunotherapy Working Party.
van Herpen CM; Jansen RL; Kruit WH; Hoekman K; Groenewegen G; Osanto S; De Mulder PH
Br J Cancer; 2000 Feb; 82(4):772-6. PubMed ID: 10732744
[TBL] [Abstract][Full Text] [Related]
9. Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.
Figlin RA; Belldegrun A; Moldawer N; Zeffren J; deKernion J
J Clin Oncol; 1992 Mar; 10(3):414-21. PubMed ID: 1482425
[TBL] [Abstract][Full Text] [Related]
10. Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report.
Miyake H; Hara I; Sakai I; Harada K; Inoue TA; Eto H; Takechi Y; Fujisawa M
Int J Clin Oncol; 2005 Oct; 10(5):338-41. PubMed ID: 16247661
[TBL] [Abstract][Full Text] [Related]
11. An outpatient phase II study of subcutaneous interleukin-2 and interferon-alpha-2b in combination with intravenous vinblastine in metastatic renal cell cancer.
Pectasides D; Varthalitis J; Kostopoulou M; Mylonakis A; Triantaphyllis D; Papadopoulou M; Dimitriadis M; Athanassiou A
Oncology; 1998; 55(1):10-5. PubMed ID: 9428369
[TBL] [Abstract][Full Text] [Related]
12. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
13. A phase I trial of weekly gemcitabine and subcutaneous interferon alpha in patients with refractory renal cell carcinoma.
Perez-Zincer F; Olencki T; Budd GT; Peereboom D; Elson P; Bukowski RM
Invest New Drugs; 2002 Aug; 20(3):305-10. PubMed ID: 12211213
[TBL] [Abstract][Full Text] [Related]
14. Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
Mani S; Vogelzang NJ; Bertucci D; Stadler WM; Schilsky RL; Ratain MJ
Cancer; 2001 Sep; 92(6):1567-76. PubMed ID: 11745236
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous interleukin-2, interferon alpha-2b and 5-fluorouracil in metastatic renal cell carcinoma as second-line treatment after failure of previous immunotherapy: a phase II trial.
Ravaud A; Trufflandier N; Ferrière JM; Debled M; Palussière J; Cany L; Gaston R; Mathoulin-Pélissier S; Bui BN
Br J Cancer; 2003 Dec; 89(12):2213-8. PubMed ID: 14676797
[TBL] [Abstract][Full Text] [Related]
16. Phase II trial of subcutaneous interleukin-2, subcutaneous interferon-alpha, 5-fluorouracil and cis-retinoic acid in the treatment of renal cell carcinoma: final results of cancer biotherapy research group 94-10.
Soori G; Dillman RO; Wiemann MC; Stark JJ; Tai F; DePriest CB; Church CK; Schulof R
Cancer Biother Radiopharm; 2002 Apr; 17(2):165-73. PubMed ID: 12030110
[TBL] [Abstract][Full Text] [Related]
17. Dose-finding trial of a combined regimen with bevacizumab, immunotherapy, and chemotherapy in patients with metastatic renal cell cancer: An Italian Oncology Group for Clinical Research (GOIRC) study.
Buti S; Lazzarelli S; Chiesa MD; Simonelli C; Re GL; Lheshi A; Simon S; Mattioli R; Caminiti C; Mazza G; Donini M; Passalacqua R;
J Immunother; 2010 Sep; 33(7):735-41. PubMed ID: 20664353
[TBL] [Abstract][Full Text] [Related]
18. Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM; Pfister C; Berdah JF; Benhammouda A; Salze P; Monnier A; Paule B; Guillet P; Chretien Y; Brewer Y; Di Palma M; Untereiner M; Malaurie E; Tadrist Z; Pavlovitch JM; Hauteville D; Mejean A; Azagury M; Mayeur D; Lucas V; Krakowski I; Larregain-Fournier D; Abourachid H; Andrieu JM; Chastang C
J Clin Oncol; 1998 Jul; 16(7):2505-13. PubMed ID: 9667271
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-2, interferon-alpha and interleukin-2 plus interferon-alpha in renal cell carcinoma. A randomized phase II trial.
Boccardo F; Rubagotti A; Canobbio L; Galligioni E; Sorio R; Lucenti A; Cognetti F; Ruggeri E; Landonio G; Baiocchi C; Besana C; Citterio G; De Rosa M; Calabresi F
Tumori; 1998; 84(5):534-9. PubMed ID: 9862512
[TBL] [Abstract][Full Text] [Related]
20. A phase I clinical trial of low-dose interferon-alpha-2A, thalidomide plus gemcitabine and capecitabine for patients with progressive metastatic renal cell carcinoma.
Amato RJ; Khan M
Cancer Chemother Pharmacol; 2008 May; 61(6):1069-73. PubMed ID: 17701037
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]